Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery

被引:29
作者
Qi, Qi [1 ]
Wei, Yidan [1 ]
Zhang, Xin [1 ]
Guan, Jian [1 ]
Mao, Shirui [1 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharm, 103 Wenhua Rd, Shenyang 110016, Peoples R China
关键词
Ocular posterior segment; Non-invasive; Topical drug delivery; Nanocarriers; NANOSTRUCTURED LIPID CARRIERS; RETINAL-PIGMENT EPITHELIUM; CONTACT-LENSES; TRIAMCINOLONE ACETONIDE; PHYSIOLOGICAL BARRIERS; POLYMERIC MICELLES; TEAR FILM; NANOPARTICLES; EYE; SEGMENT;
D O I
10.1016/j.jconrel.2023.07.055
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Posterior segment diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR) are vital factor that seriously threatens human vision health and quality of life, the treatment of which poses a great challenge to ophthalmologists and ophthalmic scientists. In particular, ocular posterior drug delivery in a noninvasive manner is highly desired but still faces many difficulties such as rapid drug clearance, limited permeability and low drug accumulation at the target site. At present, many novel non-invasive topical ocular drug delivery systems are under development aiming to improve drug delivery efficiency and biocompatibility for better therapy of posterior segment oculopathy. The purpose of this review is to present the challenges in the noninvasive treatment of posterior segment diseases, and to propose strategies to tackle these bottlenecks. First of all, barriers to ocular administration were introduced based on ocular physiological structure and behavior, including analysis and discussion on the influence of ocular structures on noninvasive posterior segment delivery. Thereafter, various routes of posterior drug delivery, both invasive and noninvasive, were illustrated, along with the respective anatomical obstacles that need to be overcome. The widespread and risky application of invasive drug delivery, and the need to develop non-invasive local drug delivery with alternative to injectable therapy were described. Absorption routes through topical administration and strategies to enhance ocular posterior drug delivery were then discussed. As a follow-up, an up-to-date research advances in non-invasive delivery systems for the therapy of ocular fundus lesions were presented, including different nanocarriers, contact lenses, and several other carriers. In conclusion, it seems feasible and promising to treat posterior oculopathy via non-invasive local preparations or in combination with appropriate devices.
引用
收藏
页码:191 / 211
页数:21
相关论文
共 201 条
[1]   Liposomes in topical ophthalmic drug delivery: an update [J].
Agarwal, Renu ;
Iezhitsa, Igor ;
Agarwal, Puneet ;
Nasir, Nurul Alimah Abdul ;
Razali, Norhafiza ;
Alyautdin, Renad ;
Ismail, Nafeeza Mohd .
DRUG DELIVERY, 2016, 23 (04) :1075-1091
[2]   Surface-modified polymeric nanoparticles for drug delivery to cancer cells [J].
Ahmed, Arsalan ;
Sarwar, Shumaila ;
Hu, Yong ;
Munir, Muhammad Usman ;
Nisar, Muhammad Farrukh ;
Ikram, Fakhera ;
Asif, Anila ;
Rahman, Saeed Ur ;
Chaudhry, Aqif Anwar ;
Rehman, Ihtasham Ur .
EXPERT OPINION ON DRUG DELIVERY, 2021, 18 (01) :1-23
[3]   Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System [J].
Akhter, Md Habban ;
Ahmad, Irfan ;
Alshahrani, Mohammad Y. ;
Al-Harbi, Alhanouf I. ;
Khalilullah, Habibullah ;
Afzal, Obaid ;
Altamimi, Abdulmalik S. A. ;
Ullah, Shehla Nasar Mir Najib ;
Ojha, Abhijeet ;
Karim, Shahid .
GELS, 2022, 8 (02)
[4]   Considerations for Polymers Used in Ocular Drug Delivery [J].
Allyn, Megan M. ;
Luo, Richard H. ;
Hellwarth, Elle B. ;
Swindle-Reilly, Katelyn E. .
FRONTIERS IN MEDICINE, 2022, 8
[5]   Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies [J].
Alshaikh, Rasha A. ;
Waeber, Christian ;
Ryan, Katie B. .
ADVANCED DRUG DELIVERY REVIEWS, 2022, 187
[6]   Characterization and Pharmacokinetics of Triamcinolone Acetonide-Loaded Liposomes Topical Formulations for Vitreoretinal Drug Delivery [J].
Altamirano-Vallejo, Juan C. ;
Navarro-Partida, Jose ;
Gonzalez-De la Rosa, Alejandro ;
Hsiao, Jane H. ;
Olguin-Gutierrez, Jose S. ;
Gonzalez-Villegas, Ana C. ;
Keller, Brian C. ;
Bouzo-Lopez, Lourdes ;
Santos, Arturo .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 34 (05) :416-425
[7]   Anti-angiogenic carbon nanovesicles loaded with bevacizumab for the treatment of age-related macular degeneration [J].
Anand, Anisha ;
Jian, Hong-Jyuan ;
Huang, Hao-Hsin ;
Hean, Li Er ;
Li, Yu-Jia ;
Lai, Jui-Yang ;
Chou, Hung-Da ;
Kang, Yu-Chuan ;
Wu, Wei-Chi ;
Lai, Chi-Chun ;
Huang, Chih-Ching ;
Chang, Huan-Tsung .
CARBON, 2023, 201 :362-370
[8]   Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye [J].
Araujo, Joana ;
Nikolic, Sasha ;
Egea, Maria A. ;
Souto, Eliana B. ;
Garcia, Maria L. .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2011, 88 (01) :150-157
[9]   Formulation development and in vitro evaluation of transferrin-conjugated liposomes as a carrier of ganciclovir targeting the retina [J].
Asasutjarit, Rathapon ;
Managit, Chittima ;
Phanaksri, Teva ;
Treesuppharat, Worapapar ;
Fuongfuchat, Asira .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 577
[10]   Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor [J].
Aukunuru, JV ;
Sunkara, G ;
Bandi, N ;
Thoreson, WB ;
Kompella, UB .
PHARMACEUTICAL RESEARCH, 2001, 18 (05) :565-572